ProstACT Global Phase 3 Update: First Patient Dosed, Part 1 Preliminary Data Plans ConfirmedTelix recently announced that its lead prostate cancer candidate TLX591 (lutetium-177 ro...
With the rapid development of precision medicine, targeted drugs have become a key approach in cancer treatment. Unlike traditional chemotherapy, targeted therapy “hits” specific...
When people hear the word “generic drug,” they often think of cheap or low-quality medicine. In fact, this is a big misunderstanding. Generic drugs are not counterfeit medicines;...
The U.S. Food and Drug Administration has granted approval to Otsuka’s newly developed injectable therapy for patients diagnosed with primary immunoglobulin A nephropathy (IgAN), ...